These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6112531)

  • 1. 5-HT2-receptor blockade in the treatment of heart failure. A preliminary study.
    Demoulin JC; Bertholet M; Soumagne D; David JL; Kulbertus HE
    Lancet; 1981 May; 1(8231):1186-8. PubMed ID: 6112531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ketanserin on hemodynamics, plasma-catecholamine concentrations, and serotonin uptake by platelets in volunteers and patients with congestive heart failure.
    Grobecker H; Gessler I; Delius W; Dominiak P; Kees F
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S102-4. PubMed ID: 2412024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketanserin, a serotonin antagonist. Administration in patients with acute respiratory failure.
    Vincent JL; Degaute JP; Domb M; Simon P; Berre J; Vandesteene A
    Chest; 1984 Apr; 85(4):510-3. PubMed ID: 6705581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular effects of ketanserin in the treatment of hypertension during coronary artery bypass surgery.
    Richter JA; Barankay A; Göb E; Späth P
    J Cardiovasc Pharmacol; 1986; 8(1):109-15. PubMed ID: 2419672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ketanserin on central haemodynamics and coronary circulation.
    Hood S; Birnie D; Nasser A; Hillis WS
    J Cardiovasc Pharmacol; 1998 Dec; 32(6):983-7. PubMed ID: 9869505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist.
    Wenting GJ; Man in 't Veld AJ; Woittiez AJ; Boomsma F; Schalekamp MA
    Br Med J (Clin Res Ed); 1982 Feb; 284(6315):537-9. PubMed ID: 6800533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of captopril in heart failure complicating acute myocardial infarction and persistence of acute haemodynamic effects in chronic heart failure after 3 years of treatment.
    Mattioli G; Ricci S; Rigo R; Fusaro MT; Cappello C
    Postgrad Med J; 1986; 62 Suppl 1():164-6. PubMed ID: 3534855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodynamic response to chronic ketanserin treatment in essential hypertension.
    Fagard R; Fiocchi R; Lijnen P; Staessen J; Amery A
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S128-9. PubMed ID: 2412034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular and blood gas responses to ketanserin in canine pulmonary edema induced by oleic acid.
    Koyama S; Kiyono S; Kayaba K; Kimura M; Nishizawa M
    Anesthesiology; 1985 Apr; 62(4):457-61. PubMed ID: 3157333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial hemodynamic effects of intravenous diazoxide in refractory congestive heart failure.
    Massie BM; Stern R; Hanlon JT; Haughom F
    Am Heart J; 1982 Sep; 104(3):581-6. PubMed ID: 7113899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular effects of ketanserin in closed-chest anesthetized dogs.
    van de Water A; Wouters L; Xhonneux R; Reneman S
    Arch Int Pharmacodyn Ther; 1985 Jun; 275(2):267-78. PubMed ID: 3161481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood pressure, 5-OH indoleacetic acid, and vanilmandelic acid excretion and blood platelet aggregation in hypertensive patients treated with ketanserin.
    Dzúrik R; Fetkovská N; Brimichová G; Tison P
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S29-31. PubMed ID: 2412052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of serotonin on the cardiopulmonary circulatory system with and without 5-HT2-receptor blockade by ketanserin.
    Breuer J; Meschig R; Breuer HW; Arnold G
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S64-6. PubMed ID: 2412062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of oxygen, nifedipine and ketanserin in hypoxic pulmonary hypertension.
    Hamet A; Král B; Cernohorský D
    Cor Vasa; 1985; 27(6):406-11. PubMed ID: 2936568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ketanserin prevents platelet aggregation and endotoxin-induced pulmonary vasoconstriction.
    Meuleman TR; Hill DC; Port JD; Stanley TH; Pace NL; Mohammad SF
    Crit Care Med; 1983 Aug; 11(8):606-11. PubMed ID: 6872549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin-induced vasoconstriction in the perfused canine femoral artery can be blocked in vivo by ketanserin.
    Meschig R; Breuer J; Arnold G
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S56-9. PubMed ID: 2412060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta blockade in congestive heart failure: persistent adverse haemodynamic effects during chronic treatment with subsequent doses.
    Kukin ML; Kalman J; Mannino MM; Buchholz-Varley C; Ocampo O
    Heart; 1997 Nov; 78(5):444-9. PubMed ID: 9415001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute hemodynamic response to the S2-serotonergic receptor antagonist, ketanserin, in patients with primary pulmonary hypertension.
    McGoon MD; Vlietstra RE
    Int J Cardiol; 1987 Mar; 14(3):303-9. PubMed ID: 3557709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in pulmonary hemodynamics predict benefits in exercise capacity after ACE inhibition in patients with mild to moderate congestive heart failure.
    Pelliccia F; Borghi A; Ruggeri A; Cianfrocca C; Morgagni GL; Bugiardini R
    Clin Cardiol; 1993 Aug; 16(8):607-12. PubMed ID: 8370193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemodynamic effects of ketanserin in the treatment of hypertension following CABG: a double-blind, placebo-controlled study.
    Vandenbroucke G; Foubert L; Evenepoel MC
    J Cardiothorac Anesth; 1989 Oct; 3(5 Suppl 1):3. PubMed ID: 2520966
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.